Trial Profile
A phase I study of Abeta oligomer displacement drug for the treatment of Alzheimer's disease
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 10 Sep 2015
Price :
$35
*
At a glance
- Drugs Amyloid beta-protein inhibitors (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- 10 Sep 2015 New trial record
- 08 Sep 2015 According to a company media release, Cognition Therapeutics plans to initiate this study by the end of 2015.